קטליסטים

AXTI · Q2 2026 actual total revenue vs ~$34M guide

AXTI · Q2 2026 actual InP revenue vs >$17M outlook

AXTI · Additional InP export permits improve shipment reliability

AXTI · Official backlog disclosure and conversion

AXTI · Q2/Q3 gross margin sustains above 30% toward 35% target

PKE · FY2027 Q1 results (revenue, gross margin, cash generation)

PKE · Q4 durability / run-rate confirmation

PKE · GE/MRAS program sales toward $34M-$38M FY2027 estimate

GRAL · FDA PMA decision (AdCom / approval / CRL / label / post-market)

GRAL · CMS publishes implementation guidance or begins a coverage process

GRAL · Commercial payers publish Galleri coverage policies

GRAL · Quarterly Galleri volume, revenue and implied ASP trend

GRAL · Peer-reviewed PATHFINDER 2 publication

GRAL · Peer-reviewed NHS-Galleri publication

NTRA · Quarterly revenue growth at/above 30%+ total / 40%+ oncology

NTRA · Disclosure of Signatera-specific revenue, oncology ASP or franchise margin

NTRA · Japan CRC commercial launch and reimbursement pricing announced

NTRA · Major commercial payer positive coverage for Signatera across solid tumors

NTRA · Gross margin holds >=64% or improves toward 66%+

NTRA · Competitor MRD data (Guardant, Exact/Abbott, Personalis, Tempus, NeoGenomics)

AXTI · Filing reconciles post-offering cash, debt, net proceeds and diluted shares

PKE · Aerojet/L3Harris/PAC-3 orders and Park-manufactured ablative growth

PKE · New-plant budget, timeline, funding and expected returns

PKE · ATM issuance and fully diluted share-count update